Economy

The U.S. agreed to exempt U.K. pharmaceutical products from tariffs.

The plan to eventually phase out rebates portends a seismic shift in the flow of billions of dollars among drugmakers, insurers and employers.

A new survey by Equitable finds that tailor-made messaging is more important than ever.

Key to cost containment lies in partnering with transparent PBMs, a more thoughtful approach to prescribing GLP-1s and encouraging the uptake of biosimilars.

While Life Insurance Awareness Month in September offers an opportunity for promotion, a year-round campaign would fill coverage gaps.

Selerix's new adviser manual boosts strategic consultations and provides holistic support for employees through a tech-driven benefits admin platform.

Without the right contractual terms in place, hidden costs may mar pooled purchasing power at the expense of employer clients.

Running a small business comes with unique challenges, and staying on top of IT needs can often feel overwhelming.

The incentives to encourage non-generic brands will encourage pharmacies to keep them in stock and increase their profits, says UnitedHealth's CEO.

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone.

President Biden's Inflation Reduction Act is expected to save taxpayers an estimated $237 billion over the next decade.

Definitive steps can be taken to strategically optimize pharmacy benefits in a way that balances cost with quality care.

CEO of WellTheory Ellen Rudolph shares her journey to diagnosis and why it inspired her to start her company.

Rising costs and ever-changing employee needs mean that employers need to reconsider their health plan model.

Health plan sponsors must know the direct and indirect compensation paid to benefit brokers, consultants and medical and prescription drug claims administrators.

A buyer's guide to best hr software for small business listing a choice of 11 vendors together with some supporting content underneath the listing.

Drug shortages have soared to a five-year peak as low profit margins discourage investment in generic manufacturing.